Compare CRWS & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | QTTB |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | United States | United States |
| Employees | 168 | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 25.1M |
| IPO Year | N/A | N/A |
| Metric | CRWS | QTTB |
|---|---|---|
| Price | $2.74 | $3.35 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.17 |
| AVG Volume (30 Days) | 107.3K | ★ 8.9M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,751,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.35 | $1.35 |
| 52 Week High | $4.69 | $28.06 |
| Indicator | CRWS | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 60.77 |
| Support Level | $2.70 | $3.23 |
| Resistance Level | $2.79 | $3.96 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 52.17 | 31.69 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.